Spec. Issue 2006 - Article Summary

Back to table of contents Spec. Issue 2006

An overview of the COLIPA eye irritation research programme

Penny Jones1, Dan Bagley2, Claudine Faller 3, Beatrice Le Varlet 4, Pauline McNamee5,
Irene Manou6, Wolfgang Pape7, Christine Van den Berghe8 and Freddy Van Goethem9

1Unilever-Safety and Environmental Assurance Centre, Colworth Park, Sharnbrook, Bedford, UK; 2Colgate-Palmolive,
Piscataway, NJ, USA; 3Cosmital Wella, Marly, Switzerland; 4LVMH Recherche, Saint Jean de Braye, France; 5The Procter &
Gamble Company, Egham, Surrey, UK; 6COLIPA, Brussels, Belgium; 7Beiersdorf, Hamburg, Germany; 8L’Oreal, Aulnay Sous
Bois, France; 9Johnson & Johnson, Pharmaceutical Research & Development, Beerse, Belgium

The COLIPA eye irritation programme incorporates research projects and collaborative activities with external partners. Three projects focus on understanding mechanisms of eye injury and identification of new in vitro endpoints that are more predictive of the in vivo human response to chemical injury: 1) investigation of whether kinetics/patterns of change in physiological function and signals of injury released from the cornea in vitro can predict a chemical’s potential to damage the eye, with a focus on recovery; 2) identification of endpoints related to the magnitude of injury and quality of repair in human immortalised cells and 3D human conjunctival and corneal constructs; 3) a genomics project using a pattern recognition approach to identify new endpoints for injury/repair that builds on corneal models from projects 1 and 2. Collaboration of industry, academia, external scientific organisations and regulators is equally important. COLIPA is working with ECVAM by actively participating in its Eye Irritation Task Force and providing support for statistical analysis of current in vitro methods.

Nach oben